Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | RAB9A | P51151 | 8/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.55 |
| ▸ | RELA | Q04206 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NCS1 | P62166 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11105682 | 1.00 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1 | |
| SCHEMBL383066 | 1.00 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1 | |
| SCHEMBL22561728 | 0.87 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1 | |
| SCHEMBL11265639 | 0.84 | PIK3CG (0.44) | NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1 | |
| SCHEMBL9963507 | 0.81 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2DYRK1AMEN1 | |
| SCHEMBL4458533 | 0.81 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1 | |
| SCHEMBL11106758 | 0.81 | DYRK1A (0.62) | NPC1RAB9ASMN1; SMN2ALDH1A1DYRK1A | |
| SCHEMBL11989036 | 0.80 | IDO1 (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1 | |
| SCHEMBL11100178 | 0.80 | PPARA (0.57) | SMN1; SMN2DYRK1ASENP7 | |
| SCHEMBL4456590 | 0.79 | ADORA1 (0.52) | NPC1RAB9ASMN1; SMN2ALDH1A1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPO-MED INC. (JP) | 2023-10-05 | — | — | US | claimed |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | claimed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | claimed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | claimed |
| EP-4190345-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | Epo-Med Inc. (JP) | 2023-06-07 | — | — | EP | claimed |
| CN-116234541-A | Treatment of diseases by EpoR antagonists | EPO医药株式会社 | 2023-06-06 | — | — | CN | claimed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | claimed |
| WO-2022025204-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | エポメッド株式会社 | 2022-02-03 | — | — | WO | claimed |
| CN-113166203-A | Anti-erythropoietin receptor peptides | EPO医药株式会社 | 2021-07-23 | — | — | CN | claimed |
| EP-3851448-A1 | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | EPO-Med Inc. (JP) | 2021-07-21 | — | — | EP | claimed |
| WO-2020054813-A1 | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | エポメッド株式会社 | 2020-03-19 | — | — | WO | claimed |
| US-20180355025-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC. | 2018-12-13 | — | — | US | claimed |
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | claimed |
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2025-08-21 | — | — | US | disclosed |
| US-12024571-B2 | Anti-erythropoietin receptor peptide | EPO-MED INC. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-4293112-A2 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | Genzyme Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPO-MED INC. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-3597655-B1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORP (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116390742-A | Cyclic chemokine-9 derivatives | 拜耳公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-4196143-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2023-06-21 | — | — | EP | disclosed |
| EP-4190345-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | Epo-Med Inc. (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-116234541-A | Treatment of diseases by EpoR antagonists | EPO医药株式会社 | 2023-06-06 | — | — | CN | disclosed |
| US-20220204963-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2022-06-30 | — | — | US | disclosed |
| WO-2022034057-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022025204-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | エポメッド株式会社 | 2022-02-03 | — | — | WO | disclosed |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2021-08-12 | — | — | US | disclosed |
| CN-113166203-A | Anti-erythropoietin receptor peptides | EPO医药株式会社 | 2021-07-23 | — | — | CN | disclosed |
| EP-3851448-A1 | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | EPO-Med Inc. (JP) | 2021-07-21 | — | — | EP | disclosed |
| US-10907142-B2 | Oligosaccharides comprising an aminooxy group and conjugates thereof | GENZYME CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3626732-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2020054813-A1 | ANTI-ERYTHROPOIETIN RECEPTOR PEPTIDE | エポメッド株式会社 | 2020-03-19 | — | — | WO | disclosed |
| EP-3191113-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3498289-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2457919-B1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORP (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20180355025-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC. | 2018-12-13 | — | — | US | disclosed |
| EP-2722051-B1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | SEATTLE GENETICS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | SEATTLE GENETICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9879046-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170369530-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-28 | — | — | US | disclosed |
| US-9850283-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2416799-B1 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | TUFTS MEDICAL CT INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2457920-B1 | Oligosaccharides comprising an aminooxy group and conjugates thereof | GENZYME CORP (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170260237-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3191113-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-LI PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170065668-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | TUFTS MEDICAL CENTER, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170014520-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-20160340391-A1 | Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| EP-2990051-B1 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | TUFTS MEDICAL CT INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9469850-B2 | Oligosaccharides comprising an aminooxy group and conjugates thereof | GENZYME CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| EP-3061460-A1 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | Tufts Medical Center, Inc. (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9376499-B2 | PAR-1 activation by metalloproteinase-1 (MMP-1) | TUFTS MEDICAL CENTER, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160158349-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-9308236-B2 | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2016039749-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80 (B7-1)/PD-LI PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2990051-A1 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | Tufts Medical Center, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2970390-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9012603-B2 | Peptides that block the binding of IgG to FcRn | BIOGEN IDEC HEMOPHILIA INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150050262-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2015019376-A1 | SYNTHETIC CYCLIC PEPTIDES, AGONISTS AND ANTAGONISTS OF UROTENSIN-II AND PROCESS FOR THE PRODUCTION THEREOF | PITARO MICHELE (IT) | 2015-02-12 | — | — | WO | disclosed |
| US-20150023975-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-22 | — | — | US | disclosed |
| US-8906844-B2 | Immunomodulatory peptides | BIOGEN IDEC HEMOPHILIA INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8889826-B2 | Peptide antibiotics and methods for making same | BIOSOURCE PHARM, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY | 2014-10-02 | — | — | US | disclosed |
| WO-2014151634-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8759501-B2 | Oligosaccharides comprising an aminooxy group and conjugates thereof | GENZYME CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2121713-B1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORP (US) | 2013-06-12 | — | — | EP | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8343928-B2 | Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus | SEATTLE GENETICS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2457920-A1 | Oligosaccharides comprising an aminooxy group and conjugates thereof | Genzyme Corporation (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457919-A1 | Oligosaccharides comprising an aminooxy group and conjugates thereof | Genzyme Corporation (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20120121706-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | TUFTS MEDICAL CENTER, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2416799-A2 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | Tufts Medical Center, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-8101186-B2 | Peptides that block the binding of IgG to FcRn | SYNTONIX PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS INC. (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2332965-A1 | Peptide antibiotics and methods for making same | BioSource Pharm, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| WO-2010118435-A2 | PAR-1 ACTIVATION BY METALLOPROTEINASE-1 (MMP-1) | TUFTS MEDICAL CENTER, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-2203471-A2 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS, INC. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100047225-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048488-A1 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| WO-2010014909-A1 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-2121713-A2 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | Genzyme Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009020867-A2 | IMMUNOMODULATORY PEPTIDES | SYNTONIX PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1991572-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20080207874-A1 | cyclopeptide intermediates are prepared from polymyxin B are used to synthesize new peptide antibiotics; readily derivatized and deprotected to provide new families of antibiotics, which have potent anti-bacterial activity against gram-negative bacteria; also are useful and potent against gram-positive | BIOSOURCE PHARM, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008089403-A2 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1917020-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | Seattle Genetics, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006083317-A9 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM INC (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007008603-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-6495693-B2 | TREATMENT OF ALZHEIMER'S DISEASE | ATHENA NEUROSCIENCES, INC. | 2002-12-17 | — | — | US | disclosed |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | AUDIA JAMES E (US) | 2001-09-06 | — | — | US | disclosed |
| US-6096782-A | N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0942923-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022493-A2 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (31 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121706-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | F2R, PLAT, F2RL1 | NPC1 3403/4885RAB9A 446/4885SMN1; SMN2 4571/4885 |
| US-10907142-B2 | Oligosaccharides comprising an aminooxy group and conjugates thereof | MAN2B1, MAN1B1, GAA | NPC1 251/4885RAB9A 757/4885SMN1; SMN2 1269/4885 |
| US-20170065668-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | F2R, F2RL1, PLAT | NPC1 3346/4885RAB9A 449/4885SMN1; SMN2 4546/4885 |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | NPC1 1942/4885RAB9A 2337/4885SMN1; SMN2 4294/4885 |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | NPC1 3559/4885RAB9A 2038/4885SMN1; SMN2 3692/4885 |
| US-20150023975-A1 | PAR-1 Activation by Metalloproteinase-1 (MMP-1) | F2R, F2RL1, PLAT | NPC1 3346/4885RAB9A 449/4885SMN1; SMN2 4546/4885 |
| US-20140294898-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | NPC1 2576/4885RAB9A 1668/4885SMN1; SMN2 4076/4885 |
| US-20150050262-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | NPC1 251/4885RAB9A 757/4885SMN1; SMN2 1269/4885 |
| US-20220204963-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | NPC1 251/4885RAB9A 757/4885SMN1; SMN2 1269/4885 |
| US-20170014520-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | NPC1 251/4885RAB9A 757/4885SMN1; SMN2 1269/4885 |
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | NPC1 3424/4885RAB9A 2182/4885SMN1; SMN2 4722/4885 |
| US-12024571-B2 | Anti-erythropoietin receptor peptide | EPOR, PRLHR, AVPR1A | NPC1 4648/4885RAB9A 2945/4885SMN1; SMN2 4254/4885 |
| US-20170260237-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | NPC1 2576/4885RAB9A 1668/4885SMN1; SMN2 4076/4885 |
| US-20100047225-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | NPC1 251/4885RAB9A 757/4885SMN1; SMN2 1269/4885 |
| US-20230303647-A1 | CYCLIC CHEMERIN-9 DERIVATIVES | CMKLR1, CMKLR2, CCL2 | NPC1 860/4885RAB9A 1325/4885SMN1; SMN2 4620/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | NPC1 3559/4885RAB9A 2038/4885SMN1; SMN2 3692/4885 |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPOR, PROKR1, HBZ | NPC1 4106/4885RAB9A 1754/4885SMN1; SMN2 378/4885 |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | NPC1 3424/4885RAB9A 2182/4885SMN1; SMN2 4722/4885 |
| US-20180355025-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | NPC1 1942/4885RAB9A 2337/4885SMN1; SMN2 4294/4885 |
| US-20170369530-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | NPC1 2576/4885RAB9A 1668/4885SMN1; SMN2 4076/4885 |
| US-20010020097-A1 | N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | APP, BACE1, IAPP | NPC1 112/4885RAB9A 1764/4885SMN1; SMN2 1398/4885 |
| US-20100048488-A1 | IMMUNOMODULATORY PEPTIDES | FCGRT, FCGR3B, FCGR2A | NPC1 4324/4885RAB9A 2919/4885SMN1; SMN2 3809/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | NPC1 1970/4885RAB9A 2318/4885SMN1; SMN2 4221/4885 |
| US-20160340391-A1 | Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions | CD274, PDCD1, PDCD1LG2 | NPC1 2576/4885RAB9A 1668/4885SMN1; SMN2 4076/4885 |
| US-10000555-B2 | Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus | PTMS, MMAB, DNPEP | NPC1 1982/4885RAB9A 2349/4885SMN1; SMN2 4336/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | NPC1 3559/4885RAB9A 2038/4885SMN1; SMN2 3692/4885 |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | NPC1 251/4885RAB9A 757/4885SMN1; SMN2 1269/4885 |
| US-20210246166-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | NPC1 3559/4885RAB9A 2038/4885SMN1; SMN2 3692/4885 |
| US-20160158349-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS | CD274, PDCD1, PDCD1LG2 | NPC1 2576/4885RAB9A 1668/4885SMN1; SMN2 4076/4885 |
| US-20080207874-A1 | cyclopeptide intermediates are prepared from polymyxin B are used to synthesize new peptide antibiotics; readily derivatized and deprotected to provide new families of antibiotics, which have potent anti-bacterial activity against gram-negative bacteria; also are useful and potent against gram-positive | VIP, PREP, PEPD | NPC1 4015/4885RAB9A 2841/4885SMN1; SMN2 4750/4885 |
| US-20110230639-A1 | IMMUNOMODULATORY PEPTIDES | FCGRT, FCGR3B, FCGR2A | NPC1 4435/4885RAB9A 3068/4885SMN1; SMN2 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.